Biosimilar development differs fundamentally from conventional generic-drug development because biological products are large, structurally complex molecules whose characteristics depend strongly on their manufacturing processes. The objective is not to create an identical molecule through chemical synthesis, but to demonstrate that the proposed biosimilar is highly similar to the reference product, with no clinically meaningful differences in safety, purity and efficacy.
A biosimilar comparability program can involve primary structure, higher-order structure, glycosylation, charge variants, aggregation, purity, process-related impurities, biological activity and functional assays. The EMA's biosimilar guidance emphasizes physicochemical characterization, biological activity, purity and relevant quality attributes as part of the comparability exercise.
A strong biosimilar program requires integration across cell line, upstream process, downstream process, analytical characterization, formulation, stability and comparability. Shilpa Biologicals identifies capabilities in cell-line development, process characterization, analytical development, bioassays and scalable manufacturing. The company's published product portfolio includes biosimilars such as adalimumab and aflibercept, recombinant human albumin, fusion proteins and monoclonal antibodies.
Analytical science is the foundation of modern biosimilar development. A well-designed analytical strategy can identify meaningful product differences early, support process optimization and provide the evidence required for regulatory comparability.
